| __timestamp | Bristol-Myers Squibb Company | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4534000000 | 104381000 |
| Thursday, January 1, 2015 | 5920000000 | 100171000 |
| Friday, January 1, 2016 | 4940000000 | 102726000 |
| Sunday, January 1, 2017 | 6411000000 | 96171000 |
| Monday, January 1, 2018 | 6345000000 | 66449000 |
| Tuesday, January 1, 2019 | 6148000000 | 42672000 |
| Wednesday, January 1, 2020 | 11143000000 | 42534000 |
| Friday, January 1, 2021 | 10195000000 | 53311000 |
| Saturday, January 1, 2022 | 9509000000 | 82258000 |
| Sunday, January 1, 2023 | 9299000000 | 118011000 |
| Monday, January 1, 2024 | 11159000000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, innovation is key. Bristol-Myers Squibb Company and Celldex Therapeutics, Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Bristol-Myers Squibb consistently outpaced Celldex, with R&D expenses peaking in 2020 at over 11 billion dollars, a staggering 25 times more than Celldex's highest annual investment. This trend highlights Bristol-Myers Squibb's commitment to innovation, as they have increased their R&D spending by approximately 105% over the years. Meanwhile, Celldex's investment, though modest in comparison, shows a steady growth, culminating in a 180% increase by 2023. This data underscores the varying scales of investment strategies between large pharmaceutical giants and smaller biotech firms, each playing a crucial role in advancing medical breakthroughs.
R&D Spending Showdown: Johnson & Johnson vs Bristol-Myers Squibb Company
Research and Development: Comparing Key Metrics for Johnson & Johnson and Celldex Therapeutics, Inc.
Research and Development Investment: AstraZeneca PLC vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Bristol-Myers Squibb Company and ACADIA Pharmaceuticals Inc.
R&D Spending Showdown: BeiGene, Ltd. vs Celldex Therapeutics, Inc.
Research and Development Expenses Breakdown: BioMarin Pharmaceutical Inc. vs Celldex Therapeutics, Inc.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Blueprint Medicines Corporation vs Celldex Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Grifols, S.A. and Celldex Therapeutics, Inc.
R&D Spending Showdown: Corcept Therapeutics Incorporated vs Celldex Therapeutics, Inc.
Comparing Innovation Spending: Celldex Therapeutics, Inc. and Viridian Therapeutics, Inc.